![Foto de María](/img/nophoto.png)
María
Buti Ferret
Publicacións nas que colabora con María Buti Ferret (14)
2024
-
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 2, pp. 201-211
2023
-
Increasing and sustaining blood-borne virus screening in Spain and Portugal throughout the COVID-19 pandemic: a multi-center quality improvement intervention
Frontiers in public health, Vol. 11, pp. 1268888
-
Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver
Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132
-
Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction
Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 150-162
-
Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B
Digestive Diseases and Sciences, Vol. 68, Núm. 6, pp. 2731-2737
2021
-
Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review
Scientific Reports, Vol. 11, Núm. 1
2019
-
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs
Journal of Hepatology, Vol. 71, Núm. 4, pp. 666-672
2018
-
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis
Gastroenterology, Vol. 155, Núm. 4, pp. 1120-1127.e4
2017
-
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort
Journal of Viral Hepatitis, Vol. 24, Núm. 4, pp. 304-311
-
Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System
Medicina Clinica, Vol. 148, Núm. 6, pp. 277-282
-
Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection
Clinical Gastroenterology and Hepatology, Vol. 15, Núm. 6, pp. 945-949.e1
-
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry
Hepatology, Vol. 65, Núm. 6, pp. 1810-1822
2015
-
Perfil clínico y seguimiento de los pacientes con hepatitis C crónica en hospitales españoles: Estudio disHCovery
Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 145-153
2014
-
Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients
Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria, Vol. 38, Núm. 5, pp. 418-429